<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584713</url>
  </required_header>
  <id_info>
    <org_study_id>EC10-345</org_study_id>
    <secondary_id>2010-024308-82</secondary_id>
    <nct_id>NCT01584713</nct_id>
  </id_info>
  <brief_title>Stromal Vascular Fraction (SVF) for Treatment of Enterocutaneous Fistula (HULPUTC)</brief_title>
  <acronym>HULPUTC</acronym>
  <official_title>A Phase II Clinical Trial to Study the Feasibility and Safety of Stromal Vascular Derived From Adipose Tissue for the Treatment of Enterocutaneous Fistula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety of Stromal Vascular Fraction (SVF) for the
      treatment of enterocutaneous fistula.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SF-12 Test
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of treatment of treated enterocutaneous fistulae. Percentage of treated subjects with closed fistulae</measure>
    <time_frame>16 weeks</time_frame>
    <description>Safety by analyzing the number of adverse effects associated with experimental treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life test</measure>
    <time_frame>16 week</time_frame>
    <description>Test SF 12 of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First efficacy data</measure>
    <time_frame>16 weeks</time_frame>
    <description>Fistula closure by radiology</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Enterocutaneous Fistula</condition>
  <arm_group>
    <arm_group_label>Adipose derived Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adipose-derived stem cells without expanded</intervention_name>
    <description>Administration will be intralesional injection of cells suspension. They will be placed into fistula walls</description>
    <arm_group_label>Adipose derived Stem Cells</arm_group_label>
    <other_name>Non applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Enterocutaneous fistula

          -  Men and women over 18 years old. Good general state of health according to the
             findings of the clinical history and the physical examination

        Exclusion Criteria:

          -  Presence of severe proctitis or dominant active luminal disease requiring immediately
             therapy

          -  Patients with an abscess unless a complete toilet of the area with drainage of the
             collections and the absence of abscess and other collections is confirmed prior to
             treatment start

          -  Patients with a history of abuse of alcohol or other addictive substances in the 6
             months prior to inclusion

          -  Patients with malignant tumor, except for basal cell or cutaneous squamous cell
             carcinoma, or patients with a prior history of malignant tumors, unless the neoplastic
             disease has been in remission for the previous 5 years

          -  Patients with cardiopulmonary disease which, in opinion of the investigator, in
             unstable or sufficiently serious to exclude the patient from the study.

          -  Patients with any type of medical or psychiatric disease which, in the opinion of the
             investigator, could be grounds for exclusion from study

          -  Patients with congenital or acquired immunodeficiencies. HIV, HBV, HCV or treponema
             infection, whether active or latent

          -  Patients who have suffering major surgery or severe trauma in the prior 6 months

          -  Pregnant or breastfeeding women

          -  Patients currently receiving, or having received within 1 month prior to enrollment
             into this clinical trial, any investigational drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Garcia-Arranz, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariano Garcia Arranz</last_name>
    <phone>+34912071022</phone>
    <email>mgarciaa.hulp@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Héctor Guadalajara Labajo</last_name>
    <phone>+34912071022</phone>
    <email>h.guadalajara@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano García Arranz</last_name>
      <phone>+34912071022</phone>
      <email>mgarciaa.hulp@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Héctor Guadalajara Labajo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damián García Olmo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tihomir G Hirstov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005 Jul;48(7):1416-23.</citation>
    <PMID>15933795</PMID>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Garcia-Arranz M, Herreros Marcos D, Pascual Miguelañez I. Fibrina y terapia celular en el tratamiento de la patología fistulosa en la enfermedad de Crohn. Protocolo y resultados de un ensayo clínico en fase I. Rev Esp Enferm Dig 2005. 97(Supl. II):51-54.)</citation>
  </reference>
  <reference>
    <citation>Herreros Marcos D, Garcia-Arranz M, Pascual Miguelañez I, Garcia-Olmo D. THE ROLE OF STEM CELLS IN SUPPURATIVE ENVIROMENTS. Experimental Dermatology 2006, 15 (6): 482.</citation>
  </reference>
  <reference>
    <citation>García Olmo D, Trébol J, Herreros D, Garcia-Arranz M, Gonzalez M. TREATMENT OF FISTULAS USING ADIPOSE-DERIVED STEM CELLS. En: García Olmo D, García-Verdugo JM, Alemany J, Gonzalez M, Gutierrez-Fuentes JA. CELL THERAPHY .2008 Ed. Mac Graw Hill. Madrid 2007</citation>
  </reference>
  <reference>
    <citation>Alvarez PD, García-Arranz M, Georgiev-Hristov T, García-Olmo D. A new bronchoscopic treatment of tracheomediastinal fistula using autologous adipose-derived stem cells. Thorax. 2008 Apr;63(4):374-6. doi: 10.1136/thx.2007.083857.</citation>
    <PMID>18364447</PMID>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther. 2008 Sep;8(9):1417-23. doi: 10.1517/14712598.8.9.1417 . Review.</citation>
    <PMID>18694359</PMID>
  </reference>
  <reference>
    <citation>Pascual I, de Miguel GF, Gómez-Pinedo UA, de Miguel F, Arranz MG, García-Olmo D. Adipose-derived mesenchymal stem cells in biosutures do not improve healing of experimental colonic anastomoses. Br J Surg. 2008 Sep;95(9):1180-4. doi: 10.1002/bjs.6242.</citation>
    <PMID>18690635</PMID>
  </reference>
  <reference>
    <citation>Vilalta M, Dégano IR, Bagó J, Gould D, Santos M, García-Arranz M, Ayats R, Fuster C, Chernajovsky Y, García-Olmo D, Rubio N, Blanco J. Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging. Stem Cells Dev. 2008 Oct;17(5):993-1003. doi: 10.1089/scd.2007.0201.</citation>
    <PMID>18537463</PMID>
  </reference>
  <reference>
    <citation>D. Garcia-Olmo, D. Herreros, I. Pascual, J. M. Pascual, E. Del-Valle, J. Zorrilla, P. De-La-Quintana, M. Garcia-Arranz, M. Pascual. EXPANDED ADIPOSE-DERIVED STEM CELLS (CX401) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA. A PHASE II CLINICAL TRIAL. Gastroenterology 2008. A833</citation>
  </reference>
  <reference>
    <citation>Garcia-Olmo, D; Guadalajara, H; Trebol, J, García-Arranz M. Expanded Adipose-Derived Stem Cells for the Treatment of Complex Perianal Fistula. HUMAN GENE THERAPY 2009. 20 (9):1028-1028</citation>
  </reference>
  <reference>
    <citation>Trebol, J; Garcia-Arranz, M; Georgiev-Hristov, T, et al. Cell Therapy for Enterocutaneous Fistula Associated with Crohn's Disease: A Clinical and Biological Comparison of Protocols With and Without Cell Expansion. HUMAN GENE THERAPY 2009. 20 (9): 1045-1045</citation>
  </reference>
  <reference>
    <citation>Garcia-Gomez, I; Olmedillas, S; Garcia-Arranz, M, et al. Adipose-Derived Stem Cells Reduce Abdominal Adhesion Formation in a Rat Experimental Model. HUMAN GENE THERAPY 2009. 20 (9): 1047-1047</citation>
  </reference>
  <reference>
    <citation>Georgiev-Hristov, T; Garcia-Olmo, D; Alvarez, PDA, et al. Use of Surgical Sutures Enriched with Adipose-Derived Stem Cells for Tracheal Anastomosis in Rats. HUMAN GENE THERAPY 2009. 20 (9): 1074-1075</citation>
  </reference>
  <reference>
    <citation>Vicente, A; Vazquez, MN; Entrena, A, Gqarcía-Arranz M,et al. BMP-4 Regulates the Expansion and Survival of Human Adipose Mesenchymal Cells. HUMAN GENE THERAPY .2009. 20 (9):1080-1081</citation>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Herreros D, Pascual M, Pascual I, De-La-Quintana P, Trebol J, Garcia-Arranz M. Treatment of enterocutaneous fistula in Crohn's Disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis. 2009 Jan;24(1):27-30. doi: 10.1007/s00384-008-0559-0. Epub 2008 Aug 12.</citation>
    <PMID>18696086</PMID>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009 Jan;52(1):79-86. doi: 10.1007/DCR.0b013e3181973487.</citation>
    <PMID>19273960</PMID>
  </reference>
  <reference>
    <citation>García-Olmo D, Herreros D, De-La-Quintana P, Guadalajara H, Trébol J, Georgiev-Hristov T, García-Arranz M. Adipose-derived stem cells in Crohn's rectovaginal fistula. Case Rep Med. 2010;2010:961758. doi: 10.1155/2010/961758. Epub 2010 Mar 7.</citation>
    <PMID>20224798</PMID>
  </reference>
  <reference>
    <citation>Pascual I, Fernández de Miguel G, García Arranz M, García-Olmo D. Biosutures improve healing of experimental weak colonic anastomoses. Int J Colorectal Dis. 2010 Dec;25(12):1447-51. doi: 10.1007/s00384-010-0952-3. Epub 2010 Jun 11.</citation>
    <PMID>20544210</PMID>
  </reference>
  <reference>
    <citation>García-Arranz M, Gómez-Pinedo U, Hardisson D, Herreros D, Guadalajara H, García-Gómez I, García-Verdugo JM, García-Olmo D. Histopathological analysis of human specimens removed from the injection area of expanded adipose-derived stem cells. Histopathology. 2010 Jun;56(7):979-82. doi: 10.1111/j.1365-2559.2010.03573.x.</citation>
    <PMID>20636801</PMID>
  </reference>
  <reference>
    <citation>García-Gómez I, Elvira G, Zapata AG, Lamana ML, Ramírez M, Castro JG, Arranz MG, Vicente A, Bueren J, García-Olmo D. Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther. 2010 Oct;10(10):1453-68. doi: 10.1517/14712598.2010.519333. Review.</citation>
    <PMID>20831449</PMID>
  </reference>
  <reference>
    <citation>Vicente López MA, Vázquez García MN, Entrena A, Olmedillas Lopez S, García-Arranz M, García-Olmo D, Zapata A. Low doses of bone morphogenetic protein 4 increase the survival of human adipose-derived stem cells maintaining their stemness and multipotency. Stem Cells Dev. 2011 Jun;20(6):1011-9. doi: 10.1089/scd.2010.0355. Epub 2010 Nov 4.</citation>
    <PMID>20846028</PMID>
  </reference>
  <reference>
    <citation>Trebol Lopez J, Georgiev Hristov T, García-Arranz M, García-Olmo D. Stem cell therapy for digestive tract diseases: current state and future perspectives. Stem Cells Dev. 2011 Jul;20(7):1113-29. doi: 10.1089/scd.2010.0277. Epub 2011 Feb 17. Review.</citation>
    <PMID>21187000</PMID>
  </reference>
  <reference>
    <citation>García-Olmo D, García-Arranz M. [Cells for curing. From the heart to everything]. An Pediatr (Barc). 2011 Apr;74(4):215-7. doi: 10.1016/j.anpedi.2011.02.021. Spanish.</citation>
    <PMID>21459345</PMID>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Herreros D, Guadalajara H, Trebol J, Georgiev T, García-Arranz M.Adipose Derived Stem Cell for Treatment of Crohn´s fistula. Histology and Histopathology. 2011; 26(ss1):356</citation>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enterocutaneous fistula</keyword>
  <keyword>Adipose Derived Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Intestinal Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

